ESMO 2022 Conference Coverage


 

ESMO 2022 Updated Results From ADAURA: Osimertinib as Adjuvant Therapy in Patients With Resected EGFRm Stage IB–IIIA NSCLC

652 views
November 8, 2022
Comments 0
Login to view comments. Click here to Login